Pharma

Your Article Summary

See Latest Articles

Pfizer Receives FDA Complete Response Letter for Lasofoxifene
Pfizer, 01/20/09

Pfizer Inc said it has received a complete response letter from the U.S. Food and Drug Administration (FDA) asking for additional information on the company’s application for lasofoxifene. The investigational compound is currently under review for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Zoster vaccination: A new opportunity for adult immunization
Canadian Journal of Infectious Diseases, 12/15/09

FDA Approves Newly Revised Prescribing Information For Azilect Reducing Medication And Food Restrictions
Teva Pharmaceutical Industries, 12/15/09

Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09

 See all of Drug/Product Approvals